Steve Sherwin, MD – Medical Oncologist
Steven Sherwin currently divides his time between advisory work for life science companies and patient care, serving on the boards of Biogen Idec, Aduro Biotech, Neurocrine Biosciences and Rigel Pharmaceuticals as directors or serving as venture partner at Third Rock Ventures.
Dr. Sherwin graduated from University Of North Carolina At Chapel Hill School Of Medicine in 1979, specializing in Obstetrics & Gynecology while practicing in Garden City, NY.
Early Life and Education
Steven Sherwin, MD is a Medical Oncology Specialist located in San Francisco. Dr. Sherwin attended Harvard University/School of Psychology before being affiliated with Zuckerberg San Francisco General Hospital and Trauma Center.
Sherwin loves spending his free time at his vineyard estate. Along with Linda, who shares his passion for winemaking, they both appreciate its cultivation at Sherwin Family Vineyards which produces an award-winning range.
Sherwin currently divides his time between advisory work in the life science industry, patient care and teaching for medical oncology patients, as well as serving on boards such as Aduro Biotech, Biogen, Neurocrine Biosciences and Rigel Pharmaceuticals; Third Rock Ventures as Venture Partner; Parker Institute for Cancer Immunotherapy’s Scientific Steering Committee as Scientific Committee member;
As a medical oncologist, Sherwin divides his time between advisory work in the life science industry and patient care and teaching. He serves as clinical professor of medicine at University of California San Francisco as well as volunteer attending physician in hematology-oncology at Zuckerberg San Francisco General Hospital. Additionally he sits on Aduro Biotech, Biogen and Neon Therapeutic boards of directors while being venture partner for Third Rock Ventures.
Cell Genesys was an immuno-oncology company specializing in GVAX and first-generation CAR T cells; he served as its chairman from 1990 until its merger with BioSante Pharmaceuticals (now ANI Pharmaceuticals) in 2009. Additionally, he founded Abgenix (an antibody company), served on its Board as founding Director and was Chairman of Ceregene (a gene therapy company later acquired by Sangamo Biosciences).
Achievement and Honors
As an active clinician, Dr. Wong has held board positions at several biotechnology companies such as Cell Genesys, Abgenix, and Ceregene and is co-authoring over 50 scientific papers.
Michael Geller served as chairman and chief executive officer of Cell Genesys until its merger with BioSante Pharmaceuticals (now ANI Pharmaceuticals) in 2009, founding and chairing Abgenix and Ceregene respectively. Additionally, he held vice-president positions for clinical research at Genentech as well as receiving his bachelor of biology with honors from Yale University.
Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching as a specialist of medical oncology. He volunteers his services at Zuckerberg San Francisco General Hospital as an attending physician, having extensive knowledge in cancer immunotherapy treatments.
Steve Sherwin’s family has deep ties to the wine business. Together with his wife, they run their own vineyard estate. Additionally, both of their children contribute their time and expertise as part of this team: Matt helps with production while Lindsey handles special events and hospitality duties.
He served as Chairman of Cell Genesys, a cancer immunotherapy company, until its merger with BioSante Pharmaceuticals (now ANI Pharmaceuticals) in October 2009. Additionally, he co-founded and was Chairman of Abgenix (an antibody company acquired by Amgen in 2006) before founding Ceregene (a gene therapy company acquired by Sangamo Biosciences in 2013).
Dr. Sherwin divides his time between advisory work and patient care. He holds academic appointments at both the University of California, Davis and Zuckerberg San Francisco General Hospital where he volunteers as Attending Physician for Hematology-Oncology Department; Third Rock Venture Partner as well as serving on boards such as Aduro Biotech, Biogen Idec, BioSante Pharmaceuticals Neurocrine Biosciences and Neon Therapeutics.
As of 2023-05-26, Sherwin’s estimated net worth stands at $6 million. He was one of the founders of Abgenix and served as its Chairman until its merger with BioSante Pharmaceuticals (now ANI Pharmaceuticals) in October 2009. Additionally, he founded Cell Genesys cancer immunotherapy company as its founding member and CEO; was a clinical researcher at Genentech; held various leadership roles at National Cancer Institute;
Sherwin has made over 20 trades of Neurocrine Biosciences stock since 2011, according to his Form 4 filings with the SEC. Most recently he exercised 30,000 units of NBIX stock valued at $385,500 on 3 January 2023 – see his full insider trading and ownership report here.